Scilex (SCLX) Competitors $0.45 -0.02 (-4.31%) Closing price 01/17/2025 04:00 PM EasternExtended Trading$0.47 +0.02 (+3.79%) As of 08:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SCLX vs. KRRO, RVNC, CTNM, GLUE, ENGN, RGNX, ALMS, TSHA, CRVS, and PGENShould you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Korro Bio (KRRO), Revance Therapeutics (RVNC), Contineum Therapeutics (CTNM), Monte Rosa Therapeutics (GLUE), enGene (ENGN), REGENXBIO (RGNX), Alumis (ALMS), Taysha Gene Therapies (TSHA), Corvus Pharmaceuticals (CRVS), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry. Scilex vs. Korro Bio Revance Therapeutics Contineum Therapeutics Monte Rosa Therapeutics enGene REGENXBIO Alumis Taysha Gene Therapies Corvus Pharmaceuticals Precigen Korro Bio (NASDAQ:KRRO) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability, community ranking, media sentiment and dividends. Do analysts rate KRRO or SCLX? Korro Bio currently has a consensus price target of $144.00, indicating a potential upside of 289.19%. Scilex has a consensus price target of $11.33, indicating a potential upside of 2,424.13%. Given Scilex's higher probable upside, analysts plainly believe Scilex is more favorable than Korro Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Korro Bio 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Scilex 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community prefer KRRO or SCLX? Korro Bio received 14 more outperform votes than Scilex when rated by MarketBeat users. CompanyUnderperformOutperformKorro BioOutperform Votes24100.00% Underperform VotesNo VotesScilexOutperform Votes10100.00% Underperform VotesNo Votes Which has more risk and volatility, KRRO or SCLX? Korro Bio has a beta of 2.03, indicating that its share price is 103% more volatile than the S&P 500. Comparatively, Scilex has a beta of 1.06, indicating that its share price is 6% more volatile than the S&P 500. Does the media refer more to KRRO or SCLX? In the previous week, Scilex had 1 more articles in the media than Korro Bio. MarketBeat recorded 5 mentions for Scilex and 4 mentions for Korro Bio. Scilex's average media sentiment score of 0.85 beat Korro Bio's score of 0.35 indicating that Scilex is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Scilex 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is KRRO or SCLX more profitable? Korro Bio has a net margin of 0.00% compared to Scilex's net margin of -159.10%. Scilex's return on equity of 0.00% beat Korro Bio's return on equity.Company Net Margins Return on Equity Return on Assets Korro BioN/A -50.25% -38.48% Scilex -159.10%N/A -93.98% Do insiders & institutionals believe in KRRO or SCLX? 13.2% of Korro Bio shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 5.4% of Korro Bio shares are held by company insiders. Comparatively, 8.7% of Scilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better earnings and valuation, KRRO or SCLX? Korro Bio has higher earnings, but lower revenue than Scilex. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKorro BioN/AN/A-$81.17MN/AN/AScilex$46.74M1.84-$114.33M-$0.83-0.54 SummaryKorro Bio beats Scilex on 8 of the 15 factors compared between the two stocks. Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCLX vs. The Competition Export to ExcelMetricScilexBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.11M$2.96B$5.33B$9.13BDividend YieldN/A1.91%5.36%4.02%P/E RatioN/A21.7162.9714.01Price / Sales1.84276.051,268.8175.41Price / CashN/A192.9344.4836.09Price / Book-0.413.964.884.58Net Income-$114.33M-$41.02M$117.85M$224.83M7 Day Performance-0.22%1.13%1.44%2.37%1 Month Performance0.34%-1.72%2.50%4.40%1 Year Performance-69.87%-2.23%25.75%20.10% Scilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCLXScilex3.9237 of 5 stars$0.45-4.3%$11.33+2,424.1%-69.9%$86.11M$46.74M0.0080Earnings ReportKRROKorro Bio1.5219 of 5 stars$36.70+4.1%$144.00+292.4%-10.0%$343.81M$14.07M0.0070RVNCRevance Therapeutics4.1952 of 5 stars$3.27+0.6%$8.39+156.4%-35.0%$341.36M$256.95M-1.69500Analyst ForecastCTNMContineum Therapeutics1.4278 of 5 stars$13.20-0.7%$29.25+121.6%N/A$340.27M$50M0.0031GLUEMonte Rosa Therapeutics3.0643 of 5 stars$5.53-3.0%$14.00+153.2%+12.1%$339.75M$14.98M-3.0290Short Interest ↑ENGNenGene2.4732 of 5 stars$7.66+0.7%$29.78+288.7%-5.4%$338.70MN/A-13.2131RGNXREGENXBIO4.3597 of 5 stars$6.81-9.3%$35.27+418.0%-46.2%$337.40M$84.33M-1.35344ALMSAlumisN/A$7.07+1.0%$26.83+279.5%N/A$333.86MN/A0.00N/APositive NewsTSHATaysha Gene Therapies3.5105 of 5 stars$1.62-8.0%$6.63+309.0%+6.3%$332.01M$9.92M2.57180CRVSCorvus Pharmaceuticals2.5636 of 5 stars$5.15-3.4%$12.38+140.3%+151.8%$330.92MN/A-5.5430Positive NewsPGENPrecigen3.9702 of 5 stars$1.07-9.4%$7.00+557.3%-13.3%$311.91M$3.96M-1.94190 Related Companies and Tools Related Companies KRRO Alternatives RVNC Alternatives CTNM Alternatives GLUE Alternatives ENGN Alternatives RGNX Alternatives ALMS Alternatives TSHA Alternatives CRVS Alternatives PGEN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SCLX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredA deadly mistake in my prediction…I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
